Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Accumulated Expenses: 2009-2016

Historic Accumulated Expenses for Northwest Biotherapeutics (NWBO) over the last 8 years, with Dec 2016 value amounting to $901,000.

  • Northwest Biotherapeutics' Accumulated Expenses fell 21.53% to $933,000 in Q1 2017 from the same period last year, while for Mar 2017 it was $933,000, marking a year-over-year decrease of 21.53%. This contributed to the annual value of $901,000 for FY2016, which is 31.17% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Accumulated Expenses stood at $901,000 for FY2016, which was down 31.17% from $1.3 million recorded in FY2015.
  • Northwest Biotherapeutics' Accumulated Expenses' 5-year high stood at $1.3 million during FY2015, with a 5-year trough of $589,000 in FY2012.
  • Moreover, its 3-year median value for Accumulated Expenses was $1.2 million (2014), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Accumulated Expenses tumbled by 79.08% in 2012, and later soared by 43.82% in 2014.
  • Yearly analysis of 5 years shows Northwest Biotherapeutics' Accumulated Expenses stood at $589,000 in 2012, then skyrocketed by 42.95% to $842,000 in 2013, then surged by 43.82% to $1.2 million in 2014, then climbed by 8.09% to $1.3 million in 2015, then tumbled by 31.17% to $901,000 in 2016.